FY2024 Earnings Estimate for TVTX Issued By Leerink Partnrs

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Stock analysts at Leerink Partnrs upped their FY2024 EPS estimates for shares of Travere Therapeutics in a research note issued to investors on Monday, January 20th. Leerink Partnrs analyst J. Schwartz now forecasts that the company will post earnings per share of ($3.99) for the year, up from their prior forecast of ($4.03). The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.92) per share. Leerink Partnrs also issued estimates for Travere Therapeutics’ Q4 2024 earnings at ($0.62) EPS, Q1 2025 earnings at ($0.59) EPS, Q2 2025 earnings at ($0.43) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at $0.32 EPS and FY2025 earnings at ($1.01) EPS.

Other equities analysts also recently issued research reports about the stock. Canaccord Genuity Group dropped their price objective on shares of Travere Therapeutics from $23.00 to $22.00 and set a “buy” rating on the stock in a report on Monday, September 30th. HC Wainwright raised their price objective on shares of Travere Therapeutics from $18.00 to $22.00 and gave the stock a “buy” rating in a report on Wednesday, January 15th. Wedbush lifted their price target on shares of Travere Therapeutics from $17.00 to $25.00 and gave the company an “outperform” rating in a report on Wednesday, October 9th. Guggenheim lifted their price target on shares of Travere Therapeutics from $23.00 to $41.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. Finally, Bank of America lifted their price target on shares of Travere Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, October 9th. One investment analyst has rated the stock with a hold rating and twelve have issued a buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

Travere Therapeutics Stock Performance

TVTX opened at $20.81 on Wednesday. The company has a current ratio of 1.71, a quick ratio of 1.68 and a debt-to-equity ratio of 24.96. The company has a market cap of $1.62 billion, a price-to-earnings ratio of -4.57 and a beta of 0.70. The company’s 50 day moving average is $18.28 and its 200 day moving average is $14.79. Travere Therapeutics has a 12-month low of $5.12 and a 12-month high of $20.89.

Travere Therapeutics (NASDAQ:TVTX) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.70) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.01. The firm had revenue of $62.90 million for the quarter, compared to the consensus estimate of $60.87 million. Travere Therapeutics had a negative net margin of 172.75% and a negative return on equity of 537.74%. The business’s quarterly revenue was up 69.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.17) EPS.

Insider Activity

In related news, CEO Eric M. Dube sold 10,736 shares of the business’s stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $19.46, for a total value of $208,922.56. Following the sale, the chief executive officer now owns 351,239 shares in the company, valued at approximately $6,835,110.94. The trade was a 2.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Roy D. Baynes sold 16,000 shares of the business’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $20.00, for a total transaction of $320,000.00. Following the completion of the sale, the director now owns 31,000 shares in the company, valued at $620,000. This represents a 34.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 62,143 shares of company stock worth $1,167,512 over the last quarter. Insiders own 3.75% of the company’s stock.

Institutional Investors Weigh In On Travere Therapeutics

Several large investors have recently bought and sold shares of the business. Baader Bank Aktiengesellschaft purchased a new position in Travere Therapeutics during the fourth quarter worth $192,000. R Squared Ltd purchased a new position in Travere Therapeutics during the fourth quarter worth $53,000. Diversified Trust Co boosted its stake in Travere Therapeutics by 27.5% during the fourth quarter. Diversified Trust Co now owns 14,701 shares of the company’s stock worth $256,000 after buying an additional 3,169 shares during the period. Virtu Financial LLC purchased a new position in Travere Therapeutics during the third quarter worth $301,000. Finally, Geode Capital Management LLC boosted its stake in Travere Therapeutics by 3.9% during the third quarter. Geode Capital Management LLC now owns 1,731,045 shares of the company’s stock worth $24,222,000 after buying an additional 64,744 shares during the period.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.